Evidence map›Paper›PMID 42569041›Full record

ArticleJTO clinical and research reports2026

Gene Expression Clustering of Lung Adenocarcinoma Tumors as a Prognosis Tool to Infer Progression-Free Survival.

Sébastien Renaut, Victoria Saavedra Armero, Dominique K Boudreau, Nathalie Gaudreault, Hanie Abolfathi, Michael Maranda-Robitaille, Fabien C Lamaze, Sabrina Biardel, Andréanne Gagné, Patrice Desmeules and 2 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sébastien RenautInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Victoria Saavedra ArmeroInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Dominique K BoudreauInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Nathalie GaudreaultInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Hanie AbolfathiInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Michael Maranda-RobitailleInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Fabien C LamazeInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Sabrina BiardelInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Andréanne GagnéInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Patrice DesmeulesInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Philippe JoubertInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Yohan BosséInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung cancer is the leading cause of cancer-related death. Studies have reported distinct tumor type based on gene expression signatures and attempted to use this information to predict survival, with limited replicability due to tumor heterogeneity, technical artefacts, and cohort size. Methods: RNA expression profiling was performed on 515 early stage resected lung adenocarcinomas from a single institution. We then used this data set to explore the potential of gene expression to stratify patients into distinct classes predictive of survival using unsupervised clustering and Cox proportional hazards model. Results: Several clinicopathologic variables, including smoking history, tumor grade, and stage, were predictive of survival. Gene expression clustering analysis supports two distinct groups of tumors as the optimal solution. Despite weak clustering of tumors based on gene expression, clusters were predictive of survival, independent of clinicopathologic variables. We also tested gene expression signatures from the literature, which were again predictive of survival, but not more than pathologic staging. Nevertheless, when restricted to early stage tumors, gene expression clustering had better predictive power than pathologic staging. Conclusion: We revealed that gene expression is naturally highly variable in tumors and that the optimal number of clusters is closer to two, instead of three as often reported. We argue that although pathologic stage remains an important predictive variable, gene expression-based biomarkers can serve as a useful prognostic tool for early stage lung adenocarcinomas.

Indexed as

Gene expressionLung adenocarcinomaProgression-free survivalUnsupervised clustering

Identifiers

PMID42569041
PMCPMC13448902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.